Revolo Biotherapeutics to Present Recently Generated Data at the 2023 AAAAI Annual Meeting Demonstrating Anti-inflammatory Effect of ‘1104 in Food Allergy
NEW ORLEANS and LONDON, February 6, 2023 – Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, today announced that recently generated preclinical data for ‘1104 in Food Allergy will be presented at the 2023 American Academy […]